Auxilium Pharmaceuticals — Investor Presentation (March 2009)
48 slides from Auxilium Pharmaceuticals's investor presentation, Mar 19, 2009
Slide 1: March 2009
March 2009 Exhibit 99.1 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 4: Anticipated XIAFLEX Events 2009-2010
• Decision from FDA on priority review (approx. 60 days post-BLA filing on Feb. 27) • Dupuytren's Contracture safety data available (post-BLA filing) • Top-line results of Peyronie's Phase IIb Study (4Q09) • FDA Approval In Dupuytren’s Contracture (early 2010) • U.S. Dupuytren’s Contracture Launch (
Slide 5: Pipeline Continues to Advance
Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy
Slide 6: Strong Strategic Partner for XIAFLEX in EU Validates Market Potential
Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pf
Slide 7: XIAFLEX Driver of Long-Term Growth
XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA
Slide 8: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener
Slide 9: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese
Slide 10: Current Treatment Options Require Invasive Surgery or Are Unapproved and Ineffective
Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation
Slide 11: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea
Slide 12: CORD I - Largest Double-blind, Placebo-controlled Trial in Dupuytren's Contracture
CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture • Primary endpoint is reduction in contracture to within - of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Seconda
Slide 13: PANY
49.1 50.2 847% 3 — | SG — | PANY [—_ — | saeshieg quauranoiduyy yA (%) Wed. 3% ll 64% (3) ssazang ya juaaieg Innovations for tite”
Slide 14: XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications
XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 7 0.
Slide 15: XIAFLEX Offers a Non-Invasive Treatment for Dupuytren's Contracture
XIAFLEX Offers a Non-Invasive Treatment for Dupuytren’s Contracture
Slide 16: Dupuytren's Key Clinical Takeaways
Dupuytren’s Key Clinical Takeaways • Efficacy should compare favorably to surgery – Primary endpoint of 5° reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake • Less severe contractures responded better than more severe contractures • MP joints r
Slide 17: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in
Slide 18: XIAFLEX Supply Chain
XIAFLEX Supply Chain • API produced in Horsham, PA – 2 ° - 8 ° C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophiliza
Slide 19: Dupuytren's Contracture – an Unmet Medical Need
Dupuytren’s Contracture –an Unmet Medical Need Tubiana 2006. Hueston 1963 Skoog 1948 Mikkelsen 1976 • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to 27 Million, in U.S. and EU, but occurs in all populations – RA is 1% of adult population • Higher prevalence in pat
Slide 20: Extensive Market Research Performed with Dupuytren's Surgeons
Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo
Slide 21: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU
Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis
Slide 22: Commercial Target for Launch of XIAFLEX in Dupuytren's Contracture
Commercial Target for Launch of XIAFLEX in Dupuytren’s Contracture Stage I Stage II Stage III Not Seeking Treatment 12.5-26 Million pts Medical and Surgical Treatment 395,000 pts Watchful Waiting 635,000 pts
Slide 23: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~ 1M patients annually seeking treatment in U.S. and EU • Sustainable patient pool – New patients within an ageing population •
Slide 24: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/
Slide 25: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith
Slide 26: Current Surgical Options - Treatment of Last Resort
Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att
Slide 27: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 28: Study 1030 / Study 1035
Study 1030 Percent of patients a-i-er Month 3 Month 6 Month 9 Study 1035 Tae : | Week6 Month3 Month6 Months a Innovations for tite”
Slide 29: Peyronie's Phase IIb Study Top-line Data Expected in 4Q09
Peyronie’s Phase IIb Study Top-line Data Expected in 4Q09 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to maintain a ri
Slide 30: Peyronie's Phase IIb Study Design
Peyronie’s Phase IIb Study Design A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 Arm Study Drug Plaque Modeling Targeted Number of Patients • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.
Slide 31: Peyronie's Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO)
Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro
Slide 32: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe
Slide 33: Annually, >210,000 Peyronie's Candidates Could Exist between U.S. and Europe
Annually , > 210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis
Slide 34: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F
Slide 35: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver
Slide 36: Testim Remains the Fastest Growing Testosterone Replacement Therapy Gel
Testim ® Remains the Fastest Growing Testosterone Replacement Therapy Gel *Mulligan T. et al. Int J. Clin Pract 2006 • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal*
Slide 37: Patient Results Were Proven in Clinical Studies
Patient Results Were Proven in Clinical Studies Total Testosterone Free Testosterone Note: Adjusted geometric means (CV b %) of a single-dose (50 mg testosterone), randomized, complete crossover study of 29 hypogonadal men. 2,000 3,000 4,000 5,000 6,000 Mean AUC 0 - 24 (ng*h/dL) Testim AndroGel Mean
Slide 38: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth
Slide 39: & a) = = S $ o cc z 2005 TRX (in thousands) 2006
& a) 3 = = S $ o cc 3 z 2005 TRX (in thousands) 2006 2007 Hl Net Revenues ($ in millions) fotal RXs (000's) Sg 6 x ! 3 $
Slide 40: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t
Slide 41: Q4 '08 Financial Results and 2009 Guidance
Revenues $34.8 $125.4 $150-155 R&D Expense $14.6 $54.5 $49-53 SG&A Expense $24.4 $89.5 $116-121 Net Loss ($12.1) ($46.3) ($50-55) Stock – Based Comp Expense $3.7 $11.7 $16-19 Cash & Cash Equivalents $113.9 Q4 ‘08 Financial Results and 2009 Guidance ($ Millions) 2009 Q4 ’08 2008 Guidance Currently ap
Slide 42: Strategic Priorities in 2009
Strategic Priorities in 2009 • Continue our pre-launch commercialization efforts and, if FDA grants a priority review for the XIAFLEX BLA for Dupuytren’s contracture, be prepared to launch in ~60 days after anticipated approval date; • Release top-line data from the XIAFLEX Peyronie’s disease Phase
Slide 43: Focused on Sustainable Long-term Growth
Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories
Slide 44: Sell-side coverage
Sell-side coverage • Jonathon Aschoff- Brean Murray • Scott Henry- Roth • Salveen Kochnover- Collins Stewart • Kimberly Lee- Pacific Growth • Lucy Lu- Citigroup • Aaron Mishel- TWP • John Newman- Oppenheimer • Josh Schimmer- FTN • Eric Schmidt- Cowen • Joe Schwartz- Leerink Swann • David Steinberg-
Slide 45: Management Contact
Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 [email protected] William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 [email protected]
Slide 46: Innovations for tite”
Innovations for tite”
Slide 47: Innovations for tite”
Innovations for tite”
Slide 48: March 2009
March 2009 (NASDAQ: AUXL)
Auxilium Pharmaceuticals — Investor Presentation (March 2009) on 6ix